2 research outputs found
袨袧袣袨袦袗袪袣袝袪蝎 小袗 125, 袧袝 4 袣袗袣 袩袪袝袛袠袣孝袨袪袧蝎袝 肖袗袣孝袨袪蝎 袩袪袨袚袧袨袟袗 校 袘袨袥鞋袧蝎啸 小 袩袨袚袪袗袧袠效袧蝎袦袠 袨袩校啸袨袥携袦袠 携袠效袧袠袣袨袙
The aim of the study was to evaluate the relationship between serum levels of tumor markers 小袗聽125 and 袧袝 4 and disease stage, histological type as well as treatment in patients with borderline ovarian tumors. Materials and methods. Thirty patients with borderline ovarian tumors were retrospectively studied. The control group consisted of 70 patients with ovarian cancer and 30 healthy women. Results. Expression levels of 小袗聽125 and 袧袝 were higher in patients with borderline tumors than in healthy women. In patients with stage I-II borderline ovarian tumors, 小袗聽125 and 袧袝 4 levels were similar to those observed in patients with ovarian cancer. However, in patients with stage III borderline ovarian tumors. After completing treatment, a significant reduction in the expression of 小袗聽125 and 袧袝 4 markers occurred. Conclusion. Tumor markers HE4 and CA125 can be predictive factors for tumor response to therapy and the tool for detecting patients at high risk for ovarian cancer
TUMOR MARKERS 小袗 125 AND 袧袝 4 AS PROGNOSTIC AND PREDICTIVE FACTORS IN BORDERLINE OVARIAN TUMORS
The aim of the study was to evaluate the relationship between serum levels of tumor markers 小袗聽125 and 袧袝 4 and disease stage, histological type as well as treatment in patients with borderline ovarian tumors. Materials and methods. Thirty patients with borderline ovarian tumors were retrospectively studied. The control group consisted of 70 patients with ovarian cancer and 30 healthy women. Results. Expression levels of 小袗聽125 and 袧袝 were higher in patients with borderline tumors than in healthy women. In patients with stage I-II borderline ovarian tumors, 小袗聽125 and 袧袝 4 levels were similar to those observed in patients with ovarian cancer. However, in patients with stage III borderline ovarian tumors. After completing treatment, a significant reduction in the expression of 小袗聽125 and 袧袝 4 markers occurred. Conclusion. Tumor markers HE4 and CA125 can be predictive factors for tumor response to therapy and the tool for detecting patients at high risk for ovarian cancer